The report on the Global Exocrine Pancreatic Insufficiency Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of a comprehensive research. The report gives a complete market analysis for the forecasted period from 2020 to 2026. The market is divided into various segments with an in-depth outlook of the competitors and a listing of the profiled key players. The market size in terms of revenue (USD MN) is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.
Study period considered for research of this market:
- Base Year: 2019
- Estimated Year: 2020
- Forecast Till: 2026
A glimpse of the major drivers and restraints affecting this market is mentioned below:
Drivers
- Increase in prevalence of diabetes
- Rise in prevalence of cystic fibrosis and chronic pancreatitis accentuates
- Increasing global incidences of exocrine pancreatic insufficiency
- Demand of advanced therapeutics and presence of significant number of pipeline drugs
- Rising geriatric population
Restraints
- Lack of technological reach
- Insufficient advanced treatments
The report offers a value chain analysis that gives a comprehensive outlook of the market. The attractiveness analysis of this market has also been included so as to evaluate the segments that are anticipated to be profitable during the forecast period.
This market has been segmented based on therapeutics such as pancreatic enzyme replacement therapy (PERT) drugs, and sollpura (liprotamase). Pancreatic enzyme replacement therapy is further bifurcated into creon, zenpep, pancreaze, ultresa, viokace, and pertzye. The study incorporates periodic market estimates and forecasts. Each therapeutics has been analyzed based on the market size at regional and country levels.
This market has been segmented based on diagnostic tests such as blood tests, endoscopic ultra-sonography (EUS), magnetic resonance imaging (MRI), and CT scanning. The report provides forecast and estimates for each diagnostic tests in terms of market size during the study period. Each diagnostic tests has been further analyzed based on regional and country levels.
Geographically, this market has been segmented into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The study details country-level aspects based on each segment and gives estimates in terms of market size.
The report also covers the complete competitive landscape of the global Exocrine Pancreatic Insufficiency market with company profiles of key players such as:
- Abbvie Inc.
- Allergan plc.
- Nordmark Arzneimittel GmbH & Co. KG
- Digestive Care, Inc.
- Cilian AG
- Anthera Pharmaceuticals Inc.
- Janssen Pharmaceuticals Inc.
- AzurRx BioPharma, Inc.
A detailed description of each has been included, with information in terms of headquarters, inception, stock listing, upcoming capacities, key mergers & acquisitions, financial overview, and recent developments. This analysis gives a thorough idea about the competitive positioning of market players. The report also gives information of the market’s mergers/acquisitions, partnerships, collaborations, new product launches, new product developments and other industry developments.
SEGMENTATIONS IN REPORT:
By Therapeutics:
- Pancreatic Enzyme Replacement Therapy (PERT) Drugs
- Creon
- Zenpep
- Pancreaze
- Ultresa
- Viokace
- Pertzye
- Sollpura (Liprotamase)
By Diagnostic Tests:
- Blood Tests
- Endoscopic Ultra-Sonography (EUS)
- Magnetic Resonance Imaging (MRI)
- CT Scanning
By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East And Africa
The Global Exocrine Pancreatic Insufficiency Market has been exhibited in detail in the following chapters -
Chapter 1 Exocrine Pancreatic Insufficiency Market Preface
Chapter 2 Executive Summary
Chapter 3 Exocrine Pancreatic Insufficiency Industry Analysis
Chapter 4 Exocrine Pancreatic Insufficiency Market Value Chain Analysis
Chapter 5 Exocrine Pancreatic Insufficiency Market Analysis By Therapeutics
Chapter 6 Exocrine Pancreatic Insufficiency Market Analysis By Diagnostic Tests
Chapter 7 Exocrine Pancreatic Insufficiency Market Analysis By Geography
Chapter 8 Competitive Landscape Of Exocrine Pancreatic Insufficiency Companies
Chapter 9 Company Profiles Of Exocrine Pancreatic Insufficiency Industry
METHODOLOGY:
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.